{
    "id": 27300,
    "fullName": "EGFR K745_E746insVPVAIK",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR K745_E746insVPVAIK results in the insertion of six amino acids in the protein kinase domain of the Egfr protein between amino acids 745 and 746 (UniProt.org). K745_E746insVPVAIK has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other EGFR exon 19 insertion mutations (PMID: 22190593).",
            "references": [
                {
                    "id": 439,
                    "pubMedId": 22190593,
                    "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22190593"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "K745_E746insVPVAIK",
    "createDate": "11/28/2017",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 135719,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174773_55174774insTACCTGTAGCAATCAAGG",
        "cDna": "c.2236_2237insTACCTGTAGCAATCAAGG",
        "protein": "p.K745_E746insVPVAIK",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12487,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 28725,
                "profileName": "EGFR K745_E746insVPVAIK"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12485,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28725,
                "profileName": "EGFR K745_E746insVPVAIK"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12486,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 28725,
                "profileName": "EGFR K745_E746insVPVAIK"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20109,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Iressa (gefitinib) treatment resulted in a partial response with a progression-free survival of 6 months in a patient with non-small cell lung cancer harboring EGFR K745_E746insVPVAIK (PMID: 31715539).",
            "molecularProfile": {
                "id": 28725,
                "profileName": "EGFR K745_E746insVPVAIK"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17697,
                    "pubMedId": 31715539,
                    "title": "Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31715539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20110,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in stable disease with a progression-free survival of 10 months in a patient with non-small cell lung cancer harboring K745_E746insVPVAIK (PMID: 31715539).",
            "molecularProfile": {
                "id": 28725,
                "profileName": "EGFR K745_E746insVPVAIK"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17697,
                    "pubMedId": 31715539,
                    "title": "Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31715539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28725,
            "profileName": "EGFR K745_E746insVPVAIK",
            "profileTreatmentApproaches": [
                {
                    "id": 16607,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR K745_E746insVPVAIK"
                },
                {
                    "id": 16608,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR K745_E746insVPVAIK"
                },
                {
                    "id": 16609,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR K745_E746insVPVAIK"
                },
                {
                    "id": 16606,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR K745_E746insVPVAIK"
                },
                {
                    "id": 16610,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR K745_E746insVPVAIK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135719,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174773_55174774insTACCTGTAGCAATCAAGG",
            "cDna": "c.2236_2237insTACCTGTAGCAATCAAGG",
            "protein": "p.K745_E746insVPVAIK",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}